Karyopharm Therapeutics Inc (KPTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $394,660
Last updated: Nov 10, 2026 at 7:59 PM ET
Karyopharm Therapeutics Inc (KPTI) Statistics
Karyopharm Therapeutics (KPTI) has a market cap of $394,660 and an enterprise value of $96.71M. Its net debt of $96.31M equals 24403.54% of its market cap. Its share count is up 235.71% from a year earlier.
Total Valuation
Enterprise value is 24403.54% above the market cap, as debt exceeds cash.
| Market Cap | $394,660 |
|---|---|
| Enterprise Value | $96.71M |
| Latest price (Nov 10, 2026) | $0.02 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 99.66% over 52 weeks and trades 97.92% below its 50-day average.
| Beta (1Y) | 1.07 |
|---|---|
| 52-Week Change | -99.66% |
| 1-Month Change | -96.56% |
| 3-Month Change | -99.14% |
| 6-Month Change | -99.80% |
| 5-Year Change | -99.19% |
| 10-Year Change | -99.39% |
| Total Return (3Y CAGR) | -88.74% |
| Total Return (5Y CAGR) | -83.17% |
| Max Drawdown (1Y) | -99.84% |
| Max Drawdown (3Y) | -99.93% |
| Sharpe Ratio (1Y) | -2.22 |
| Correlation with SPY (1Y) | 0.05 |
| 50-Day Average | $0.96 |
| 200-Day Average | $5.81 |
| 52-Week Range | $0.02 to $10.99 |
| RSI (14 Days) | 28.0 |
| Average Volume (20 Days) | 24.12M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.79x current liabilities.
| Current Ratio | 0.79x |
|---|---|
| Quick Ratio | 0.76x |
| Interest Coverage | -1.03x |
Returns and Efficiency
Return on invested capital is 64.55% over the last 12 months, against a 5-year average of 78.82%.
| Return on Assets (ROA) | -201.89% |
|---|---|
| Return on Invested Capital (ROIC) | 64.55% |
| ROA (5Y Average) | -74.72% |
| ROIC (5Y Average) | 78.82% |
| Asset Turnover | 1.36x |
| Inventory Turnover | 1.59x |
| Receivables Turnover | 5.51x |
| Cash Conversion Cycle | -65 days |
Scores
KPTI has an Altman Z-Score of -25.66, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -25.66 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $146.62M over the last 12 months is up 6.81% from the 12 months before.
| Revenue | $146.62M |
|---|---|
| Revenue Growth (YoY) | +6.81% |
| Gross Profit | $140.59M |
| Operating Income | -$82.35M |
| Pretax Income | -$224.77M |
| Net Income | -$224.74M |
| EBIT | -$115.48M |
| Reported EPS (TTM) | -$9.61 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
| Cash and Equivalents | $54.98M |
|---|---|
| Total Debt | $151.29M |
| Net Debt | $96.31M |
| Net Debt Per Share | $3.33 |
| Working Capital | -$27.86M |
| Shareholder Equity | -$330.17M |
| Total Assets | $111.32M |
| Total Liabilities | $441.49M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Operating Cash Flow | -$65.35M |
|---|---|
| FCF Per Share | -$2.88 |
| Depreciation and Amortization | $10.19M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -56.17%, against a 5-year average of -74.08%.
| Gross Margin | 95.89% |
|---|---|
| Operating Margin | -56.17% |
| Pretax Margin | -153.30% |
| Net Margin | -153.28% |
| EBIT Margin | -78.76% |
| Gross Margin (5Y Average) | 96.69% |
| Operating Margin (5Y Average) | -74.08% |
| Net Margin (5Y Average) | -89.84% |
Growth
Revenue fell 2.39% a year over 3 years.
| Revenue Growth (3Y CAGR) | -2.39% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.21% |
Dividends and Yields
KPTI does not pay a dividend.
| Buyback Yield | -11530.60% |
|---|---|
| Shareholder Yield | -11530.60% |
Stock Splits
The last split was a 1-for-15 reverse split on Feb 26, 2025.
| Last Split Date | Feb 26, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 5 similar companies, KPTI has the 3rd highest ROIC.
ROICPeer median -61.86%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| ROIC | 64.55% vs -61.86% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +6.81% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 8.75% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +8.75% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KPTI
What is KPTI's market cap?
Karyopharm Therapeutics has a market cap of $394,660. Its enterprise value, which adds debt and subtracts cash, is $96.71M.
How many shares of KPTI are outstanding?
Karyopharm Therapeutics has 28.94M shares outstanding. The count is up 235.71% from a year earlier.
Does KPTI pay a dividend?
No. Karyopharm Therapeutics does not pay a dividend.
How much debt does KPTI have?
Karyopharm Therapeutics has $151.29M of total debt and $54.98M of cash and equivalents, a net debt position of $96.31M.
KPTI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors